KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) FCF Margin (2016 - 2025)

Neogenomics (NEO) has disclosed FCF Margin for 16 consecutive years, with 9.87% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, FCF Margin rose 2706.0% year-over-year to 9.87%, compared with a TTM value of 0.48% through Dec 2025, up 564.0%, and an annual FY2025 reading of 0.48%, up 564.0% over the prior year.
  • FCF Margin was 9.87% for Q4 2025 at Neogenomics, up from 0.3% in the prior quarter.
  • Across five years, FCF Margin topped out at 22.44% in Q3 2021 and bottomed at 65.01% in Q4 2021.
  • Average FCF Margin over 5 years is 8.5%, with a median of 4.85% recorded in 2022.
  • The sharpest move saw FCF Margin plummeted -6063bps in 2021, then skyrocketed 6196bps in 2022.
  • Year by year, FCF Margin stood at 65.01% in 2021, then surged by 95bps to 3.05% in 2022, then tumbled by -118bps to 6.64% in 2023, then crashed by -159bps to 17.19% in 2024, then skyrocketed by 157bps to 9.87% in 2025.
  • Business Quant data shows FCF Margin for NEO at 9.87% in Q4 2025, 0.3% in Q3 2025, and 7.72% in Q2 2025.